OS from a risk-defining event occurring after initiation of therapy with bendamustine and rituximab in patients with advanced stage FL treated in BC. Outcomes in patients experiencing early progression (POD24) were poor, with 2 year postprogression survival estimated at 38% (95% CI 20-55%), which is markedly inferior to that observed in the reference group.